- Home
- GBLI vs MAZE Comparison
GBLI vs MAZE Comparison
Compare GBLI & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- MAZE
- Stock Information
- Founded
- GBLI 2016
- MAZE 2018
- Country
- GBLI United States
- MAZE United States
- Employees
- GBLI N/A
- MAZE N/A
- Industry
- GBLI Property-Casualty Insurers
- MAZE
- Sector
- GBLI Finance
- MAZE
- Exchange
- GBLI Nasdaq
- MAZE NYSE
- Market Cap
- GBLI 435.4M
- MAZE 367.0M
- IPO Year
- GBLI 2003
- MAZE 2025
- Fundamental
- Price
- GBLI $30.79
- MAZE $14.90
- Analyst Decision
- GBLI
- MAZE Strong Buy
- Analyst Count
- GBLI 0
- MAZE 5
- Target Price
- GBLI N/A
- MAZE $25.60
- AVG Volume (30 Days)
- GBLI 1.9K
- MAZE 149.7K
- Earning Date
- GBLI 08-06-2025
- MAZE 08-14-2025
- Dividend Yield
- GBLI 4.55%
- MAZE N/A
- EPS Growth
- GBLI N/A
- MAZE N/A
- EPS
- GBLI 1.99
- MAZE 0.34
- Revenue
- GBLI $437,447,000.00
- MAZE $167,500,000.00
- Revenue This Year
- GBLI $7.67
- MAZE N/A
- Revenue Next Year
- GBLI $7.93
- MAZE N/A
- P/E Ratio
- GBLI $15.46
- MAZE $44.42
- Revenue Growth
- GBLI N/A
- MAZE N/A
- 52 Week Low
- GBLI $26.94
- MAZE $6.71
- 52 Week High
- GBLI $37.00
- MAZE $19.19
- Technical
- Relative Strength Index (RSI)
- GBLI 48.44
- MAZE N/A
- Support Level
- GBLI $30.10
- MAZE N/A
- Resistance Level
- GBLI $32.03
- MAZE N/A
- Average True Range (ATR)
- GBLI 0.62
- MAZE 0.00
- MACD
- GBLI 0.00
- MAZE 0.00
- Stochastic Oscillator
- GBLI 24.73
- MAZE 0.00
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.